Literature DB >> 20497050

Redirection of the immune response to the functional catalytic domain of the cystein proteinase cruzipain improves protective immunity against Trypanosoma cruzi infection.

Silvia I Cazorla1, Fernanda M Frank, Pablo D Becker, María Arnaiz, Gerardo A Mirkin, Ricardo S Corral, Carlos A Guzmán, Emilio L Malchiodi.   

Abstract

Despite the strong immune responses elicited after natural infection with Trypanosoma cruzi or vaccination against it, parasite survival suggests that these responses are insufficient or inherently inadequate. T. cruzi contains a major cystein proteinase, cruzipain, which has a catalytic N-terminal domain and a C-terminal extension. Immunizations that employed recombinant cruzipain or its N- and C-terminal domains allowed evaluation of the ability of cruzipain to circumvent responses against the catalytic domain. This phenomenon is not a property of the parasite but of cruzipain itself, because recombinant cruzipain triggers a response similar to that of cruzipain during natural or experimental infection. Cruzipain is not the only antigen with a highly immunogenic region of unknown function that somehow protects an essential domain for parasite survival. However, our studies show that this can be reverted by using the N-terminal domain as a tailored immunogen able to redirect host responses to provide enhanced protection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20497050     DOI: 10.1086/652872

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection.

Authors:  Natacha Cerny; Andrés Sánchez Alberti; Augusto E Bivona; Mauricio C De Marzi; Fernanda M Frank; Silvia I Cazorla; Emilio L Malchiodi
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

2.  Tc52 amino-terminal-domain DNA carried by attenuated Salmonella enterica serovar Typhimurium induces protection against a Trypanosoma cruzi lethal challenge.

Authors:  Marina N Matos; Silvia I Cazorla; Augusto E Bivona; Celina Morales; Carlos A Guzmán; Emilio L Malchiodi
Journal:  Infect Immun       Date:  2014-07-28       Impact factor: 3.441

Review 3.  Advances and challenges towards a vaccine against Chagas disease.

Authors:  Israel Quijano-Hernandez; Eric Dumonteil
Journal:  Hum Vaccin       Date:  2011-11-01

4.  Recombinant Cysteine Proteinase B from Leishmania braziliensis and Its Domains: Promising Antigens for Serodiagnosis of Cutaneous and Visceral Leishmaniasis in Dogs.

Authors:  A E Bivona; L Czentner; A Sanchez Alberti; N Cerny; A C Cardoso Landaburu; C Nevot; O Estévez; J D Marco; M A Basombrio; E L Malchiodi; S I Cazorla
Journal:  J Clin Microbiol       Date:  2019-10-23       Impact factor: 5.948

5.  Recombinant Mycobacterium bovis BCG is a promising platform to develop vaccines against Trypansoma cruzi infection.

Authors:  I Bontempi; K Leal; E Prochetto; G Díaz; G Cabrera; A Bortolotti; H R Morbidoni; S Borsuk; O Dellagostin; I Marcipar
Journal:  Clin Exp Immunol       Date:  2020-07-06       Impact factor: 4.330

6.  The Immune Response to Trypanosoma cruzi: Role of Toll-Like Receptors and Perspectives for Vaccine Development.

Authors:  Mauricio M Rodrigues; Ana Carolina Oliveira; Maria Bellio
Journal:  J Parasitol Res       Date:  2012-02-16

7.  Subdominant/cryptic CD8 T cell epitopes contribute to resistance against experimental infection with a human protozoan parasite.

Authors:  Mariana R Dominguez; Eduardo L V Silveira; José Ronnie C de Vasconcelos; Bruna C G de Alencar; Alexandre V Machado; Oscar Bruna-Romero; Ricardo T Gazzinelli; Mauricio M Rodrigues
Journal:  PLoS One       Date:  2011-07-14       Impact factor: 3.240

8.  Repertoire, genealogy and genomic organization of cruzipain and homologous genes in Trypanosoma cruzi, T. cruzi-like and other trypanosome species.

Authors:  Luciana Lima; Paola A Ortiz; Flávia Maia da Silva; João Marcelo P Alves; Myrna G Serrano; Alane P Cortez; Silvia C Alfieri; Gregory A Buck; Marta M G Teixeira
Journal:  PLoS One       Date:  2012-06-07       Impact factor: 3.240

9.  Cruzipain Activates Latent TGF-β from Host Cells during T. cruzi Invasion.

Authors:  Patrícia Mello Ferrão; Claudia Masini d'Avila-Levy; Tania Cremonini Araujo-Jorge; Wim Maurits Degrave; Antônio da Silva Gonçalves; Luciana Ribeiro Garzoni; Ana Paula Lima; Jean Jacques Feige; Sabine Bailly; Leila Mendonça-Lima; Mariana Caldas Waghabi
Journal:  PLoS One       Date:  2015-05-04       Impact factor: 3.240

10.  Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi.

Authors:  Raquel Tayar Nogueira; Alanderson Rocha Nogueira; Mirian Claudia Souza Pereira; Maurício Martins Rodrigues; Patrícia Cristina da Costa Neves; Ricardo Galler; Myrna Cristina Bonaldo
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.